NAMI
SUPN icon

Nomura Asset Management International’s Supernus Pharmaceuticals SUPN Stock Holding History

Nomura Asset Management International’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$111M Buy
2,378,329
+341,127
+17% +$16.4M 0.17% 128
2026
Q1 		$105M Sell
2,037,202
-270,437
-12% -$13.8M 0.18% 123
2025
Q4 		$115M Buy
+2,307,639
New +$112M 0.17% 140

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Nomura Asset Management International's SUPN Position: Q2 2026 in Review

Nomura Asset Management International increased its Supernus Pharmaceuticals (SUPN) stake by 17% in Q2 2026, buying an estimated $16.4M and bringing the position to 2,378,329 shares worth $111M. The position accounts for 0.17% of the portfolio, ranked #128.

Nomura Asset Management International first reported a position in SUPN in Q4 2025 and has held it in 3 quarters since. The position peaked at $115M in Q4 2025. 331 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Nomura Asset Management International held 2,378,329 shares of Supernus Pharmaceuticals worth $111M as of Q2 2026.
  • Nomura Asset Management International bought 341,127 Supernus Pharmaceuticals shares in Q2 2026, an estimated $16.4M.
  • Supernus Pharmaceuticals made up 0.17% of Nomura Asset Management International's portfolio in Q2 2026, its #128 holding.
  • Nomura Asset Management International first reported a position in Supernus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Nomura Asset Management International's Supernus Pharmaceuticals position peaked at $115M in Q4 2025.
  • 331 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Nomura Asset Management International's 13F filing for Q2 2026, filed 14 Aug 2026.